MLTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MoonLake Immunotherapeutics (MLTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock has strong positive catalysts, favorable analyst ratings, and a clear regulatory path for its key drug, sonelokimab. Despite the lack of recent Intellectia trading signals, the pre-market price increase and positive sentiment make this a solid long-term investment opportunity.
The MACD is above 0 and positively contracting, indicating mild bullish momentum. RSI is neutral at 46.85, and moving averages are converging, suggesting no strong directional trend. Key support is at 16.513, and resistance is at 19.348. Pre-market price is $18.14, up 1.97%, showing positive sentiment.
Multiple analyst upgrades with significant price target increases (e.g., Wolfe Research to $24, Rothschild & Co to $40, Clear Street to $70).
Positive regulatory progress for sonelokimab, with a clear path for approval in hidradenitis suppurativa.
Favorable clinical data and potential new market opportunities in axial spondyloarthritis.
Goldman Sachs maintains a Sell rating with a price target of $11, citing doubts about sonelokimab's approvability.
Financials show no revenue and a net loss of $62.4M in Q4 2025, though losses have narrowed YoY.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $62.4M, which improved by 36.89% YoY. EPS increased to -0.92, up 27.78% YoY. Despite no revenue, the narrowing losses indicate improving financial health.
Analyst sentiment is overwhelmingly positive, with multiple upgrades and price target increases. Wolfe Research, Rothschild & Co, and Clear Street highlight the potential of sonelokimab and its regulatory progress, while only Goldman Sachs remains bearish with a Sell rating.
